Startups
BioStem Technologies (OTC: BSEM)
Edit

BioStem Technologies (OTC: BSEM)

Trusted
https://www.biostemtechnologies.com/
Last activity: 19.09.2026
Active
Categories: BioTechDevelopmentGrowthHealthTechManagementManufacturingProductResearch
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain processing method. BioRetain has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB"). These systems and procedures are established per current Good Tissue Practices ("cGTP") and current Good Manufacturing Processes ("cGMP"). Our portfolio of quality brands includes VENDAJE, VENDAJE AC, and VENDAJE OPTIC. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida.
Followers
114
Followers
1.05K
Website visits
2.5K /mo.
Mentions
6

Overview

Location
United States, Florida, Pompano Beach
Employees
11-50
Founded date
2014

Mentions in press and media 6

DateTitleDescription
Sign up to seeSign up to seeSign up to see
Apr 17, 2025Terumo Blood and Cell Technologies Names Patrick Daly as Chief Business OfficerDaly, a 30-year veteran of the healthcare industry, is the latest leadership addition to help Terumo BCT unite business areas and fuel enterprise growth LAKEWOOD, Colo., April 17, 2025 /PRNewswire/ -- Terumo Blood and Cell Technologies (Ter...
Aug 29, 2024BioStem Technologies, Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ETAdvanced wound care MedTech company recently reported a record second-quarter with $116.4M in revenue for H1, 2024 POMPANO BEACH, Fla., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focu...
Nov 3, 2023BioStem Technologies Closes Oversubscribed $2M Private Placement
Mar 25, 2021BIOSTEM TECHNOLOGIES INC BioStem Technologies : Receives TRIP (TRG Rapid Inquiry Program) Response for VENDAJE™Pompano Beach, Fl., March 25, 2021 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company"), a pre-clinical-stage biotechnology company focused on harnessing elements of perinatal tiss...
BioStem Technologies“Change descriptor to - BioStem Technologies, Inc. (OTCQB: BSEM) is a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care.”

Reviews 0

Sign up to leave a review

Sign up Log In

FAQ about BioStem Technologies (OTC: BSEM)

When was BioStem Technologies (OTC: BSEM) founded?

BioStem Technologies (OTC: BSEM) was founded in 2014.

What has the press written about BioStem Technologies (OTC: BSEM)?

Parsers VC has collected 6 articles mentioning BioStem Technologies (OTC: BSEM), among them “Terumo Blood and Cell Technologies Names Patrick Daly as Chief Business Officer” (Apr 17, 2025) and “BioStem Technologies, Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET” (Aug 29, 2024).

Is BioStem Technologies (OTC: BSEM) still active?

Yes, BioStem Technologies (OTC: BSEM) is active; its latest activity on Parsers VC dates from Sep 19, 2026.